Medicine recalls
|
| |
| Batch Recall of Tykerb Tablets 250mg |
| |
The Department of Health (DH) today (August 28) endorsed a licensed drug wholesaler, namely Zuellig Pharma Limited (Zuellig), the distributor appointed by the holder of certificate of drug registration, Novartis Pharmaceuticals (HK) Limited (Novartis), to voluntarily recall one batch (batch number: RD0944) of registered pharmaceutical product, namely Tykerb Tablets 250mg (Hong Kong Registration number: HK-67443) from the market due to quality issue.
The DH received notification from Novartis that the overseas manufacturer of the product is recalling the above batch due to out of specification of dissolution test in the affected batch. Therefore, Novartis voluntarily recalls the affected batch from the market.
The above product, containing lapatinib, is a prescription medicine indicated for the treatment of breast cancer. According to Novartis, the above product was imported into Hong Kong and distributed by Zuellig and has been supplied to the Hospital Authority, local private doctors and pharmacies.
Novartis has set up a hotline (8203 6077) to answer related enquiries.
So far, the DH has not received any adverse reaction reports in connection with the above batch of product. The DH will closely monitor the recall.
Patients who are taking the above product should not stop taking the medicine, but should seek advice from their healthcare professionals as soon as possible for appropriate arrangements.
End/Friday, August 28, 2026
|
| |
